Impact of BMI on serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D with calcifediol supplementation in young adults: a longitudinal study.
1,25(OH)2D
BMI
Calcifediol
Cholecalciferol
Vitamin D supplementation
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
10
05
2024
accepted:
27
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
High body mass index (BMI) is a risk factor for vitamin D deficiency. The rise in serum 25-hydroxyvitamin D [25(OH)D] concentrations following cholecalciferol supplementation is suboptimal, owing to adipose tissue sequestration and/or volumetric dilution. Calcifediol is a proven potent oral alternative for vitamin D supplementation, but whether BMI adversely affects its efficacy in raising 25(OH)D concentrations, is not well known. Adults with serum concentrations of 25(OH)D < 30 ng/mL were recruited and stratified as normal, overweight, or obese using WHO criteria. Baseline evaluation included 25(OH)D, parathyroid hormone (PTH), and total 1,25-dihydroxyvitamin D [1,25(OH) Participants were stratified as obese (11.2%), overweight (32.1%), or normal weight (56.7%). There were no significant baseline differences in serum concentrations of 25(OH)D among the groups (13.1 ± 6.4 vs 12.8 ± 6.8 vs 11.6 ± 6.6 ng/mL, p = 0.62). Similarly, PTH or 1,25(OH) BMI does not impede the rise in 25(OH)D concentrations following supplementation with calcifediol in young adults with vitamin D deficiency.
Sections du résumé
BACKGROUND
BACKGROUND
High body mass index (BMI) is a risk factor for vitamin D deficiency. The rise in serum 25-hydroxyvitamin D [25(OH)D] concentrations following cholecalciferol supplementation is suboptimal, owing to adipose tissue sequestration and/or volumetric dilution. Calcifediol is a proven potent oral alternative for vitamin D supplementation, but whether BMI adversely affects its efficacy in raising 25(OH)D concentrations, is not well known.
MATERIAL AND METHODS
METHODS
Adults with serum concentrations of 25(OH)D < 30 ng/mL were recruited and stratified as normal, overweight, or obese using WHO criteria. Baseline evaluation included 25(OH)D, parathyroid hormone (PTH), and total 1,25-dihydroxyvitamin D [1,25(OH)
RESULTS
RESULTS
Participants were stratified as obese (11.2%), overweight (32.1%), or normal weight (56.7%). There were no significant baseline differences in serum concentrations of 25(OH)D among the groups (13.1 ± 6.4 vs 12.8 ± 6.8 vs 11.6 ± 6.6 ng/mL, p = 0.62). Similarly, PTH or 1,25(OH)
CONCLUSION
CONCLUSIONS
BMI does not impede the rise in 25(OH)D concentrations following supplementation with calcifediol in young adults with vitamin D deficiency.
Identifiants
pubmed: 38861119
doi: 10.1007/s12020-024-03895-0
pii: 10.1007/s12020-024-03895-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
R. Bouillon, J.M. Gomez, Comparison of calcifediol with vitamin D for prevention or cure of vitamin D deficiency. J. Steroid Biochem. Mol. Biol. 228, 106248 (2023)
H. Mazahery, P.R. Von Hurst, Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients 7(7 Jun), 5111–5142 (2015)
doi: 10.3390/nu7075111
pubmed: 26121531
pmcid: 4516990
A. Didriksen, G. Grimnes, M.S. Hutchinson, M. Kjærgaard, J. Svartberg, R.M. Joakimsen, R. Jorde, The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. Eur. J. Endocrinol. 169(5 Nov), 559–567 (2013)
doi: 10.1530/EJE-13-0233
pubmed: 23935129
D.K. Tobias, H. Luttmann-Gibson, S. Mora, J. Danik, V. Bubes, T. Copeland, M.S. LeBoff, N.R. Cook, I.M. Lee, J.E. Buring, J.E. Manson, Association of Body Weight With Response to Vitamin D Supplementation and Metabolism. JAMA Netw. Open 6(1 Jan), e2250681 (2023)
doi: 10.1001/jamanetworkopen.2022.50681
pubmed: 36648947
pmcid: 9856931
R. Khadgawat, R.K. Marwaha, M.K. Garg, R. Ramot, A.K. Oberoi, V. Sreenivas, M. Gahlot, N. Mehan, P. Mathur, N. Gupta, Impact of vitamin D fortified milk supplementation on vitamin D status of healthy school children aged 10–14 years. Osteoporos. Int. 24(Aug), 2335–2343 (2013)
doi: 10.1007/s00198-013-2306-9
pubmed: 23460234
R.K. Marwaha, M.K. Garg, G. Sethuraman, N. Gupta, A. Mithal, N. Dang, M. Kalaivani, M.A. Ganie, A. Narang, P. Arora, A. Singh, Impact of three different daily doses of vitamin D3 supplementation in healthy schoolchildren and adolescents from North India: a single-blind prospective randomised clinical trial. Br. J. Nutr. 121(5 Mar), 538–548 (2019)
doi: 10.1017/S0007114518003690
pubmed: 30843501
A. Tayde, M. Mittal, R. Khadgawat, S. Sharma, V. Sreenivas, A. Rai, Response to single oral dose vitamin D in obese vs non-obese vitamin D–deficient children. Eur. J. Pediatrics 180(Apr), 1043–1050 (2021)
doi: 10.1007/s00431-020-03831-0
B.W. Hollis, C.L. Wagner, The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J. Clin. Endocrinol. Metab. 98(12 Dec), 4619–4628 (2013)
doi: 10.1210/jc.2013-2653
pubmed: 24106283
pmcid: 3849670
N. Charoenngam, T.A. Kalajian, A. Shirvani, G.H. Yoon, S. Desai, A. McCarthy, C.M. Apovian, M.F. Holick, A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. Am. J. Clin. Nutr. 114(3 Sep), 1189–1199 (2021)
doi: 10.1093/ajcn/nqab123
pubmed: 34008842
pmcid: 8408845
J. Jakobsen, E.A. Andersen, T. Christensen, R. Andersen, S. Bügel, Vitamin D vitamers affect vitamin D status differently in young healthy males. Nutrients 10(1 Dec), 12 (2017)
doi: 10.3390/nu10010012
pubmed: 29295513
pmcid: 5793240
A. Shieh, C. Ma, R.F. Chun, S. Witzel, B. Rafison, H.T. Contreras, J. Wittwer-Schegg, L. Swinkels, T. Huijs, M. Hewison, J.S. Adams, Effects of cholecalciferol vs calcifediol on total and free 25-hydroxyvitamin D and parathyroid hormone. J. Clin. Endocrinol. Metab. 102(4 Apr), 1133–1140 (2017)
doi: 10.1210/jc.2016-3919
pubmed: 28187226
pmcid: 5460735
A. Shieh, S.M. Lee, V. Lagishetty, C. Gottleib, J.P. Jacobs, J.S. Adams, Pilot trial of vitamin D3 and calcifediol in healthy vitamin D deficient adults: does it change the fecal microbiome? J. Clin. Endocrinol. Metab. 106(12 Nov), 3464–3476 (2021)
pubmed: 34343292
pmcid: 8864755
S. Bhat, L. Das, D. Maheshwari, D. Badal, R. Sarkar, M. Gupta, S.S. Pandav, B.K. Padhi, S.K. Bhadada, M.F. Holick, P. Dutta, Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial. J. Infect. 86(5 May), e120–e122 (2023)
doi: 10.1016/j.jinf.2023.03.004
pubmed: 36889512
pmcid: 10008192
R. Jorde, M. Sneve, N. Emaus, Y. Figenschau, G. Grimnes, Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study. Eur. J. Nutr. 49(Oct), 401–407 (2010)
doi: 10.1007/s00394-010-0098-7
pubmed: 20204652
E. Jodar, C. Campusano, R.T. de Jongh, M.F. Holick, Calcifediol: a review of its pharmacological characteristics and clinical use in correcting vitamin D deficiency. Eur. J. Nutr. 62(4 Jun), 1579–1597 (2023)
doi: 10.1007/s00394-023-03103-1
pubmed: 36862209
pmcid: 9979899
J.M. Quesada-Gomez, R. Bouillon, Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos. Int. 29(Aug), 1697–1711 (2018)
doi: 10.1007/s00198-018-4520-y
pubmed: 29713796
A. Jetter, A. Egli, B. Dawson-Hughes, H.B. Staehelin, E. Stoecklin, R. Goessl, J. Henschkowski, H.A. Bischoff-Ferrari, Pharmacokinetics of oral vitamin D3 and calcifediol. Bone 59(Feb), 14–19 (2014)
doi: 10.1016/j.bone.2013.10.014
pubmed: 24516879
G. Targher, L. Bertolini, L. Scala, M. Cigolini, L. Zenari, G. Falezza, G. Arcaro, Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr., Metab. Cardiovascular Dis. 17(7 Sep), 517–524 (2007)
doi: 10.1016/j.numecd.2006.04.002
P.T. James, R. Leach, E. Kalamara, M. Shayeghi, The worldwide obesity epidemic. Obes. Res. 9(S11 Nov), 228S–233SS (2001)
pubmed: 11707546
V. Camozzi, A.C. Frigo, M. Zaninotto, F. Sanguin, M. Plebani, M. Boscaro, L. Schiavon, G. Luisetto, 25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese. Osteoporos. Int. 27(Aug), 2593–2602 (2016)
doi: 10.1007/s00198-016-3574-y
pubmed: 27026331
W. Saliba, O. Barnett-Griness, G. Rennert, The relationship between obesity and the increase in serum 25 (OH) D levels in response to vitamin D supplementation. Osteoporos. Int. 24(Apr), 1447–1454 (2013)
doi: 10.1007/s00198-012-2129-0
pubmed: 22955311
M.B. Snijder, R.M. van Dam, M. Visser, D.J. Deeg, J.M. Dekker, L.M. Bouter, J.C. Seidell, P. Lips, Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J. Clin. Endocrinol. Metab. 90(7 Jul), 4119–4123 (2005)
doi: 10.1210/jc.2005-0216
pubmed: 15855256
G. Muscogiuri, G.P. Sorice, A. Prioletta, C. Policola, S. Della Casa, A. Pontecorvi, A. Giaccari, 25‐Hydroxyvitamin D concentration correlates with insulin‐sensitivity and BMI in obesity. Obesity 18(10 Oct), 1906–1910 (2010)
doi: 10.1038/oby.2010.11
pubmed: 20150902
A.T. Drincic, L.A. Armas, E.E. Van Diest, R.P. Heaney, Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity 20(7 Jul), 1444–1448 (2012)
doi: 10.1038/oby.2011.404
pubmed: 22262154
J.C. Tang, S. Jackson, N.P. Walsh, J. Greeves, W.D. Fraser, The dynamic relationships between the active and catabolic vitamin D metabolites, their ratios, and associations with PTH. Sci. Rep. 9(1 May), 6974 (2019)
doi: 10.1038/s41598-019-43462-6
pubmed: 31061425
pmcid: 6502854
H.A. Bischoff‐Ferrari, B. Dawson‐Hughes, E. Stöcklin, E. Sidelnikov, W.C. Willett, J.O. Edel, H.B. Stähelin, S. Wolfram, A. Jetter, J. Schwager, J. Henschkowski, Oral supplementation with 25 (OH) D3 versus vitamin D3: effects on 25 (OH) D levels, lower extremity function, blood pressure, and markers of innate immunity. J. Bone Miner. Res. 27(1 Jan), 160–169 (2012)
doi: 10.1002/jbmr.551
pubmed: 22028071
S. Gonnelli, M.D. Tomai Pitinca, S. Camarri, B. Lucani, B. Franci, R. Nuti, C. Caffarelli,, Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women. Aging Clin. Exp. Res. 33(9), 2539–2547 (2021).
doi: 10.1007/s40520-020-01779-7
pubmed: 33506314
pmcid: 8429405